Good pipeline news. Watching. R/S tomorrow 1:30.
A secondary, obviously, yes
Yes of course I did. What's next? LOL
did you miss this today also?
This site used to be very popular, not anymore.
I remember 20 years ago was different, we all moved to other apps and platforms.
Yeah, I have been seeing this lately. Stocks, running, and no one’s on iHub.
Thank you DollarDan.
BioSpace put out this story yesterday. Maybe it is the reason.
NOPE---------Just us chickens
oh ya and reindeer
Are there any catalysts here?
Over reaction to some not so great new.
Rich getting richer, Go $CRBP!
Bad test results.
ROCE Insights For Corbus Pharmaceuticals
2/2/21, 10:44 AM
February 2, 2021 10:44 AM ET (BZ Newswire) -- Earnings
During Q3, Corbus Pharmaceuticals (NASDAQ:CRBP) brought in sales totaling $1.23 million. However, earnings decreased 10.92%, resulting in a loss of $33.97 million. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss.
Why ROCE Is Significant
Changes in earnings and sales indicate shifts in Corbus Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Corbus Pharmaceuticals posted an ROCE of -1.16%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Corbus Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.
In Corbus Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.
Q3 Earnings Insight
Corbus Pharmaceuticals reported Q3 earnings per share at $-0.43/share, which did not meet analyst predictions of $-0.42/share.
Copyright © 2021 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to firstname.lastname@example.org with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
The Financials look like shit
don't pay to much attntion to pre-market. It,s easier to manipulate. I like to see they make it pullback and clean the market
It looks horrible right now, what gives? Offering was at $6, the only thing is shorts are piling on.
By the trading, it looks not today lol